Latest News & Features
Big Pharma
Increasing numbers of patent challengers are finding the USPTO’s post-grant procedures to be attractive alternatives to district court litigation, write Arlene Chow and Peter Noh. 29 September 2014
Genetics
Pluristem develops therapies using cells from the placenta that have been cultured in a unique way. LSIPR finds out how the company protects and nourishes its technologies. 4 September 2014
Americas
Sifting through the published comments on the USPTO’s Myriad/Mayo guidelines, LSIPR found them to be overwhelmingly negative. 4 September 2014
Big Pharma
For those who can draw an informative patent map and work out a good navigational route through the complexities, there is an opportunity to gain significant competitive advantages through making the right partnerships, argue Quentin Tannock and Anna Duch. 4 September 2014
Generics
HemoShear creates systems for predicting human responses to drugs by applying its proprietary technology
to human cells in the lab to make them behave the way they would in vivo. LSIPR found out about its strategy for protecting and developing its technologies. 1 August 2014
Big Pharma
Parties need to take care when considering interim injunctions and keep an eye on future IP litigation, says Jan Lindberg. 1 August 2014
article
The development of gene technologies is still at a relatively early stage, with patent applications coming from research institutes and universities as well as industry. Gareth Williams has crunched the numbers. 1 August 2014
Biotechnology
The EPO generally accepts applications relating to human embryonic stem cells with an effective date after 2008 but discussions about eligibility continue, says Joachim Wachenfeld. 7 July 2014
Generics
The PharmaSea project is working to make viable drug candidates of novel compounds found under the sea. LSIPR discovers how the EU-funded initiative does it. 7 July 2014
Americas
Acting against infringers can involve the pharmaceutical regulatory framework and civil law as well as following the more usual pathways, says José R. Trigueros. 20 June 2014